Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Technetium tc99m mertiatide is a radiopharmaceutical agent used in nuclear medicine primarily for dynamic renal imaging. After intravenous injection, it rapidly binds to plasma proteins and is excreted mainly via **active tubular secretion** with some contribution from glomerular filtration. The radiolabeled compound emits gamma rays detectable by gamma cameras, allowing assessment of renal perfusion, function, drainage, and detection of congenital or acquired kidney abnormalities, obstruction, or calculi in adults and children. The agent is widely used to indirectly evaluate effective renal plasma flow, particularly in patients with possible renovascular hypertension, chronic kidney disease, and post-renal transplantation surveillance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on technetium tc99m mertiatide.